Semaglutide

Clinical maturity: Approved, multiple completed Phase 3 programmes and cardiovascular outcome trials

Approved products are subcutaneous injections (Ozempic, Wegovy). An oral semaglutide tablet (Rybelsus) exists for type 2 diabetes with different indications and absorption constraints — the same molecule is not the same product, and evidence from one formulation does not automatically transfer to another.

Route availability is not evidence of efficacy, and evidence from one route does not transfer to another. The Registry never provides dosing or sourcing information.

A long-acting synthetic analogue of GLP-1, a gut hormone released after eating. It slows gastric emptying, increases glucose-dependent insulin release and acts on appetite circuits in the brain.

• Substantial and sustained weight loss
• Improved blood glucose control in type 2 diabetes
• Reduced cardiovascular events in higher-risk groups
• Reduces 'food noise'

This is one of the rare cases where the marketing and the evidence are roughly in the same postcode. Large randomised trials show clinically meaningful weight loss and glycaemic improvement, with outcome data in specific higher-risk populations. Effects depend on continued use; discontinuation is generally followed by partial weight regain.

• Multiple large randomised, placebo-controlled Phase 3 trials in type 2 diabetes and obesity.
• Cardiovascular outcome trials in defined higher-risk populations.
• Long-term extension data on weight maintenance and regain after stopping.

• Extensive rodent work on appetite circuits, gastric emptying and islet function.
• Rodent thyroid C-cell tumour findings that drive a labelled contraindication for people with a personal or family history of medullary thyroid carcinoma or MEN2.

Animal and cell findings are Level 1–2 evidence.

• GLP-1 receptor agonism in pancreatic beta cells increases glucose-dependent insulin secretion.
• Central GLP-1 receptor signalling in hypothalamic and brainstem circuits reduces appetite and reward-driven eating.
• Delayed gastric emptying increases fullness after meals.

• Very common: nausea, vomiting, constipation, diarrhoea — usually dose-related and often settling over time.
• Notable: gallbladder events, pancreatitis (uncommon), dehydration from persistent vomiting.
• Muscle and bone loss alongside fat loss is an active research topic; resistance training and protein intake are widely discussed but not a substitute for clinical guidance.

Approved in multiple regions for type 2 diabetes and, in separate formulations, for weight management. In March 2024 the FDA approved Wegovy to reduce the risk of cardiovascular death, heart attack and stroke in adults with established cardiovascular disease and overweight or obesity, and in August 2025 granted accelerated approval for Wegovy in adults with noncirrhotic MASH with moderate-to-advanced (F2-F3) fibrosis. Every approval is product- and indication-specific.

• 2024-03-08 · United States

  FDA approved Wegovy to reduce the risk of cardiovascular death, heart attack and stroke in adults with established cardiovascular disease and overweight or obesity.

• 2025-08 · United States

  FDA granted accelerated approval to Wegovy for adults with noncirrhotic MASH with moderate-to-advanced liver fibrosis (F2-F3).

• L5Practice-changingPhase 3 weight management programme

  Randomised, double-blind, placebo-controlled — Adults with obesity or overweight with comorbidity

  Substantial average weight reduction versus placebo, sustained with continued treatment.

• Long-term registry data resolving the thyroid signal in humans either way.
• Head-to-head outcome trials against newer multi-receptor agonists.

• Regulatory / labelFDA press release — Wegovy approved to reduce risk of serious heart problems in adults with obesity or overweight (8 March 2024)
• Regulatory / labelWegovy prescribing information (FDA label, incl. MASH accelerated approval)

Source hierarchy: regulatory documents and trial registries first, peer-reviewed work next, sponsor material flagged as non-independent. We never use supplier or clinic marketing as evidence, and where a verified source has not yet been curated we say so rather than inventing one.

No recorded changes yet. Baseline position set on 2026-08-23.